Breaking News Instant updates and real-time market news.

ALXN

Alexion

$123.22

(0.00%)

, TRIP

TripAdvisor

$53.23

(0.00%)

09:40
11/06/18
11/06
09:40
11/06/18
09:40

Unusually active option classes on open November 6th

Unusual total active option classes on open include: Alexion (ALXN), TripAdvisor (TRIP), Credit Suisse (CS), ProShares UltraShort Lehman 20 plus Year Treasury (TBT), Mylan (MYL), NIO Inc (NIO), Booking Holdings (BKNG), Bausch Health (BHC), CVS Health (CVS), and Merck (MRK).

ALXN

Alexion

$123.22

(0.00%)

TRIP

TripAdvisor

$53.23

(0.00%)

CS

Credit Suisse

$12.77

(0.00%)

TBT

ProShares UltraShort 20+ yr Trsry

$41.32

(0.00%)

MYL

Mylan

$31.36

(0.00%)

NIO

NIO Inc.

$6.67

(0.00%)

BKNG

Booking Holdings

$1,881.90

(0.00%)

BHC

Bausch Health

$25.55

(0.00%)

CVS

CVS Health

$73.71

(0.00%)

MRK

Merck

$73.11

(0.00%)

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 08

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 26

    Nov

  • 27

    Nov

  • 01

    Dec

  • 11

    Jan

  • 15

    Feb

  • 16

    Feb

  • 18

    Feb

  • 25

    Feb

ALXN Alexion
$123.22

(0.00%)

10/10/18
10/10/18
UPGRADE

Strong Buy
RA Pharmaceuticals upgraded to Strong Buy ahead of Phase 2 data at Raymond James
As previously reported, Raymond James upgraded RA Pharmaceuticals (RARX) to Strong Buy from Outperform with a $28 price target. Analyst Steven Seedhouse expects Phase 2 data for lead subcutaneous C5 inhibitor zilucoplan in generalized myasthenia gravis expected around YE18 to demonstrate a treatment benefit in a mixed refractory/non-refractory patient population and be competitive with Alexion's (ALXN) Soliris. Seedhouse believes a positive Phase 2 readout could be worth $1B in market cap at least and could treat a broader population of patients than Soliris given subcutaneous administration and pricing leverage.
10/15/18
PIPR
10/15/18
NO CHANGE
PIPR
Piper lists names to own in Biopharma after recent selloff
Piper Jaffray's biopharma analyst team highlighted names to own in the Biopharma sector following the recent selloff of the broader market. The firm's ideas include: Adamas Pharmaceuticals (ADMS), Agios Pharmaceuticals (AGIO), Agios Pharmaceuticals (ALNY), Alexion (ALXN), Bluebird Bio (BLUE), BioMarin (BMRN), CymaBay (CBAY), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), Jazz Pharmaceuticals (JAZZ), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and Xencor (XNCR).
10/24/18
PIPR
10/24/18
NO CHANGE
Target $177
PIPR
Overweight
Piper 'perplexed' by Alexion earnings selloff, says buy shares
Piper Jaffray analyst Christopher Raymond recommends using the selloff today in shares of Alexion Pharmaceuticals (ALXN) as a buying opportunity. The company reported "yet another strong beat/raise quarter and continued impressive pipeline progress," Raymond tells investors in a research note. The analyst sees "little to quibble with commercially" with Soliris' "continued strength and a rapidly expanding margin profile." Raymond is "perplexed" by the stock pullback and keeps an Overweight rating on Alexion with a $177 price target. The stock could be weak on fears over Roche's (RHHBY) update on RG6107, the analyst adds. He says Alexion remains one of his favorite large caps to own "well into 2019."
10/31/18
HCWC
10/31/18
NO CHANGE
Target $24
HCWC
Buy
Dicerna price target raised to $24 after Lilly, Alexion pacts at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target on Dicerna (DRNA) shares to $24 from $20 after the company announced collaborations with Eli Lilly (LLY) and Alexion Pharmaceuticals (ALXN). Arce views these partnerships as further strong validation of Dicerna's GalXC RNAi platform and keeps a Buy rating on the shares.
TRIP TripAdvisor
$53.23

(0.00%)

10/25/18
10/25/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Caterpillar (CAT) upgraded to Hold from Sell at DZ Bank with analyst Robert Czerwensky upgrading the stock but lowering his price target to $119 from $127. 2. Tesla (TSLA) upgraded to Outperform from Peer Perform at Wolfe Research with analyst Dan Galves saying Q3 non-GAAP earnings of $2.90, versus consensus of 3c, and free cash flow of $881M is proof that Tesla's earnings power is likely to outperform traditional automakers. 3. Hilton (HLT) upgraded to Buy from Neutral at B. Riley FBR with analyst Jeffrey Donnelly saying the significant year-to-date underperformance of the shares, the majority of which took place in October, has created an attractive entry point. 4. Owens Corning (OC) upgraded to Overweight from Equal Weight at Barclays with analyst Matthew Bouley saying "Diminishing headwinds" in 2019 to support earnings growth off of a depressed base. 5. TripAdvisor (TRIP) upgraded to Neutral from Underperform at Credit Suisse with analyst Stephen Ju citing upcoming quarterly results. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/25/18
10/25/18
UPGRADE
Target $51

Neutral
TripAdvisor upgraded to Neutral ahead of Q3 results at Credit Suisse
As previously reported, Credit Suisse analyst Stephen Ju upgraded TripAdvisor to Neutral from Underperform ahead of quarterly results. The analyst also raised his price target on the shares to $51 from $44.
10/25/18
FBCO
10/25/18
UPGRADE
FBCO
Neutral
TripAdvisor upgraded to Neutral from Underperform at Credit Suisse
10/16/18
10/16/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Abbott (ABT), Boston Scientific (BSX), Stryker (SYK), and Medtronic (MDT) were initiated with an Overweight at Barclays, while Baxter (BAX), Edwards Lifesciences (EW), and Zimmer Biomet (ZBH) were initiated with an Underweight. 2. Expedia (EXPE) was initiated with an Outperform at Evercore ISI, while TripAdvisor (TRIP) was initiated with an In Line, and Booking Holdings (BKNG) was initiated with an In Line. 3. Facebook (FB) was initiated with a Buy at Loop Capital and Rosenblatt. 4. Snap (SNAP) initiated with a Hold at Loop Capital. 5. VF Corp. (VFC) initiated with a Neutral at Wedbush. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CS Credit Suisse
$12.77

(0.00%)

09/10/18
LEHM
09/10/18
UPGRADE
LEHM
Equal Weight
Credit Suisse upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Amit Goel upgraded Credit Suisse to Equal Weight with a price target of 16 francs. The risk/reward looks more balanced at current share levels, Goel tells investors in a research note. However, the analyst expects the trading environment to remain difficult in the near-term. He sees continued downside risk to consensus estimates.
11/02/18
11/02/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Neutral from Buy at BofA/Merrill with analyst Wamsi Mohan citing his concern that there are likely to be further negative estimate revisions. 2. American Tower (AMT) downgraded to Hold on 'full valuation' at Deutsche Bank with analyst Matthew Niknam saying he sees risk to estimates and a "full valuation" at current share levels. 3. Credit Suisse (CS) downgraded to Hold from Buy at Societe Generale. 4. Puma Biotechnology (PBYI) downgraded to Underweight from Equal Weight at Barclays, to Underweight from Overweight at JPMorgan, and to Underperform from Buy at BofA/Merrill. 5. UPS (UPS) downgraded to Neutral from Buy at Citi with analyst Christian Wetherbee lowering his price target for the shares to $115 from $125. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/02/18
SOCG
11/02/18
DOWNGRADE
SOCG
Hold
Credit Suisse downgraded to Hold from Buy at Societe Generale
09/10/18
09/10/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Foot Locker (FL) upgraded to Outperform from Market Perform at Wells Fargo with analyst Tom Nikic saying after 12-18 months of choppy operating performance, he believes that brighter days are ahead for Foot Locker due primarily to improvement in the Nike-brand (NKE) assortment, an alleviation of the Jordan-brand headwind and an alleviation of the headwinds in Europe. 2. Kennametal (KMT) upgraded to Buy from Neutral at Longbow. 3. Credit Suisse (CS) upgraded to Equal Weight from Underweight at Barclays with analyst Amit Goel saying the risk/reward looks more balanced at current share levels. 4. Cenovus Energy (CVE) upgraded to Overweight from Neutral at JPMorgan with analyst Phil Gresh saying the company's rail deal with Canadian National (CNI) and its deleveraging will unlock "cheap" free cash flow yield. 5. Akamai (AKAM) upgraded to Buy from Neutral at DA Davidson with analyst Mark Kelleher citing his meeting with management last week to discuss its Q2 results and the company direction going into 2019. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TBT ProShares UltraShort 20+ yr Trsry
$41.32

(0.00%)

MYL Mylan
$31.36

(0.00%)

11/06/18
COWN
11/06/18
NO CHANGE
Target $31
COWN
Market Perform
Mylan business model looks broken, says Cowen
Cowen analyst Ken Cacciatore said Mylan's Q3 results confirm his thesis that the current business model looks broken. He said at some point a new product cycle needs to materialize, but in Mylan's case it hasn't happened in a material enough way. Cacciatore recommends avoiding the shares and he reiterated his Market Perform rating and $31 price target on Mylan.
11/06/18
11/06/18
UPGRADE
Target $42

Buy
Mylan upgraded to Buy after 'encouraging' Q3 report at BofA/Merrill
As previously reported, BofA Merrill Lynch analyst Jason Gerberry upgraded Mylan to Buy from Neutral, stating that its Q3 report provided encouraging updates regarding several of its business segments. He believes concerns around its broader portfolio look overdone as industry-level generic pricing is showing signs of stabilizing while the company also provided encouraging new product updates. Gerberry added that he views the 20% stock pullback as an attractive opportunity, but trimmed his price target on Mylan shares to $42 from $44 to reflect rebasing of EpiPen and generic Copaxone.
11/06/18
BOFA
11/06/18
UPGRADE
BOFA
Buy
Mylan upgraded to Buy from Neutral at BofA/Merrill
11/06/18
MZHO
11/06/18
NO CHANGE
Target $39
MZHO
Neutral
Mylan target raised to $39 on 'comforting' Q3 results at Mizuho
Mylan reported "comforting" Q3 results with $300M in high margin new product sales and reiterated its 2018 guidance, Mizuho analyst Irina Koffler tells investors in a post-earnings research note. The analyst raised her price target for the shares to $39 from $37 and reiterates a Neutral rating on the name.
NIO NIO Inc.
$6.67

(0.00%)

10/09/18
MSCO
10/09/18
INITIATION
Target $8.5
MSCO
Overweight
NIO Inc. initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Jack Yeung initiated NIO Inc. with an Overweight rating and $8.50 price target, projecting a sales volume CAGR of 54.5% in 2017-22 for China's premium EV market and contending that NIO's price advantage over foreign competitors will allow it to penetrate the market. He notes that NIO's ES8, the company's first mass-produced model, has best-in-class specifications but a lower price, partly due to local manufacturing subsidies, the absence of customs duties and reduced taxes.
10/22/18
FBCO
10/22/18
INITIATION
Target $12.6
FBCO
Outperform
Credit Suisse starts NIO Inc. with an Outperform rating, $12.60 price target
Credit Suisse analyst Bin Wang initated NIO Inc. with an Outperform rating and $12.60 price target, stating that the company has a well-establish premium branding in China and is a leader in smart electric vehicle technology. He estimates NIO's revenue will grow at a 192% CAGR to 2020 and sees the company achieving its first year of breakeven in 2021, when Wang assumes it will be able to produce 165,000 units.Target $12.60.
10/09/18
10/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Outperform at Macquarie. 2. Tellurian (TELL) initiated with a Buy at BofA/Merrill. 3. NIO Inc. (NIO) initiated with a Neutral at JPMorgan and an Overweight at Morgan Stanley. 4. Eyenovia (EYEN) initiated with a Buy at H.C. Wainwright. 5. Garrett Motion (GTX) initiated with an Equal Weight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/09/18
JPMS
10/09/18
INITIATION
Target $7.5
JPMS
Neutral
NIO Inc. initiated with a Neutral at JPMorgan
JPMorgan analyst Nick Lai started NIO Inc. with a Neutral rating and $7.50 price target. The analyst wants to see a track record of execution before getting more constructive on the shares and adds that potential further capital raising could also be a risk before the company turns a profit in 2021.
BKNG Booking Holdings
$1,881.90

(0.00%)

11/06/18
SUSQ
11/06/18
NO CHANGE
Target $2300
SUSQ
Positive
Booking Holdings price target raised to $2,300 from $2,200 at Susquehanna
Susquehanna analyst Shyam Patil raised his price target on Booking Holdings to $2,300 from $2,200 following its Q3 results. The analyst likes its secular opportunity to penetrate hotels and alternative accommodations room nights. He believes the room night growth acceleration will ease fears around perpetual growth deceleration. Patil reiterated his Positive rating on Booking Holdings shares.
11/06/18
MSCO
11/06/18
NO CHANGE
Target $2100
MSCO
Overweight
Booking Q3 results, Q4 outlook illustrate 'multiple levers,' says Morgan Stanley
Morgan Stanley analyst Brian Nowak said Booking Holdings' Q3 room nights growth being 200bp better than expected and its Q4 guidance, with the top end of room nights growth being 100bp better than expected, speak to the multiple levers the company has to pull. He is particularly bullish about the percentage of room nights coming from direct channels increasing year-over-year and the fact that direct traffic remains the largest source of new customer growth. Nowak keeps an Overweight rating and $2,100 price target on Booking shares.
11/06/18
DADA
11/06/18
NO CHANGE
Target $2000
DADA
Neutral
Booking Holdings price target nudged higher to $2,000 at DA Davidson
DA Davidson analyst Tome White raised his price target on Booking Holdings to $2,000 from $1,980 after its "strong" Q3 top-line beat and a 1% EBITDA upside, saying the 12% growth in gross bookings was also above his 5% estimate. The analyst notes however that the performance was also supported by the "later summer peak travel and higher growth from paid marketing channels," adding that the management is also prepared to "tolerate margin compression" to achieve above-industry growth rate in 2019. White also keeps his Neutral rating on Booking Holdings, noting its 20-times forward earnings valuation multiple.
11/06/18
FBCO
11/06/18
NO CHANGE
Target $2240
FBCO
Outperform
Booking Holdings price target raised to $2,240 from $2,100 at Credit Suisse
Credit Suisse analyst Stephen Ju raised his price target for Booking Holdings to $2,240 from $2,100 following quarterly results. The analyst reiterates an Outperform rating on the shares.
BHC Bausch Health
$25.55

(0.00%)

10/08/18
WELS
10/08/18
NO CHANGE
WELS
Underperform
Bausch Health approval of Bryhali largely expected, says Wells Fargo
Bausch Health announced this morning that final approval of Bryhali Lotion for the treatment of plaque psoriasis in adults is pending the expiration of exclusivity for a related product, which is expected to occur in early November, Wells Fargo analyst David Maris tells investors in a research note. The analyst reiterates his belief that the market largely expected Bausch would receive approval for Bryhali since the active ingredient is already available as a generic and other similar products are already approved using this active ingredient. While unaware the approval would be held up based on the exclusivity of another product, Maris does not consider the one or two month delay as significant. He currently models Bryhali sales of $17M in 2019, and peak sales of approximately $75M. Maris keeps an Underperform rating on shares of Bausch Health, which are trading up 4% to $27.37 in early trading.
10/15/18
MZHO
10/15/18
NO CHANGE
Target $35
MZHO
Buy
Bausch Health Q3 consensus estimates have upside, says Mizuho
Mizuho analyst Irina Koffler sees potential upside to Bausch Health's Q3 consensus estimates and she reiterates a Buy rating on the shares with a $35 price target. The analyst expects "strong" Xifaxan growth to persist into 2019 and believes that the Alcon spin valuation may provide a positive read-through to Bausch's B+L segment valuation.
11/05/18
MSCO
11/05/18
UPGRADE
MSCO
Overweight
Bausch Health upgraded to Overweight from Equal Weight at Morgan Stanley
11/05/18
11/05/18
UPGRADE
Target $32

Overweight
Bausch Health upgraded to Overweight on improving growth at Morgan Stanley
As previously reported, Morgan Stanley analyst David Risinger upgraded Bausch Health to Overweight from Equal Weight, as he expects improved growth in 2020, a mix shift toward new products and gradual debt paydown to drive the stock's multiple higher. He continues to project Q3 EBITDA of $850M, 5% above consensus, and sees the upcoming quarterly report as a potential catalyst to drive the stock up, Risinger added. He set a $32 price target on Bausch Health shares.
CVS CVS Health
$73.71

(0.00%)

10/31/18
PIPR
10/31/18
DOWNGRADE
Target $206
PIPR
Neutral
Piper downgrades Aetna to Neutral on confidence of CVS deal closing
Piper Jaffray analyst Sarah James last night downgraded Aetna (AET) to Neutral from Overweight and lowered her price target for the shares to $206 from $212. The analyst is favorable on the fundamentals of Aetna's business and is confident the CVS Health (CVS) takeover will close given the recent Department of Justice approval. She believes Aetna shares will be range bound near the $206 per share takeout price.
10/25/18
WOLF
10/25/18
INITIATION
WOLF
Peer Perform
CVS Health initiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Justin Lake assumed coverage on CVS Health with a Peer Perform citing moderating 2019 business momentum and limited growth visibility across the pharmacy and PBM businesses.
10/22/18
FBCO
10/22/18
NO CHANGE
Target $207
FBCO
Neutral
Aetna price target raised to $207 from $202 at Credit Suisse
Credit Suisse analyst A.J. Rice raised his price target for Aetna (AET) to $207 from $202, while reiterating a Neutral rating on the shares. The analyst noted that the DOJ preliminary approved CVS' (CVS) acquisition of Aetna after the latter reached an agreement to sell its Medicare Part D drug plan business to WellCare Health Plans. Connecticut approved the CVS-AET deal October 17, and New York is expected to reach a decision after October 25, Rice adds. At this point, the analyst feels deal approval has a high probability of occurring, albeit the timing could be slightly later than CVS' outlook of early Q4 closing. Overall, Rice is putting a 90%-95% probability on the deal closure.
09/20/18
LEER
09/20/18
NO CHANGE
Target $250
LEER
Outperform
Cigna price target raised to $250 from $235 at Leerink
Leerink analyst Ana Gupte raised her price target on Outperform-rated Cigna (CI) to $250 from $235 following meetings with a panel of PBM and Specialty Rx specialists, which increased her bullishness on Cigna and Market Perform-rated Express Scripts (ESRX). In a research note to investors, Gupte says she also came away with raised confidence on the achiveability of the $4B annual drug cost savings from the Express Scripts switch by Anthem (ANTM) to IngenioRx in partnership with CVS (CVS). She adds that smaller independent PBMs still have niche opportunities with smaller regional third-party health plans, noting that Magellan Health (MGLN) is well positioned in this market, though loss of substantial business in Florida Seriously Mentally Ill is a headwind in Rx as well.
MRK Merck
$73.11

(0.00%)

10/31/18
SBSH
10/31/18
NO CHANGE
Target $84
SBSH
Buy
Merck price target raised to $84 from $79 at Citi
Citi analyst Andrew Baum raised his price target for Merck to $84 and reiterates a Buy rating on the shares. The analyst says his 20%-plus above consensus non-GAAP earnings estimates beyond 2022 are driven by a continued view that the market underestimates Merck's market share in the PDx and PARP spaces with Keytruda and Lynparza respectively.
10/22/18
BMOC
10/22/18
NO CHANGE
Target $82
BMOC
Outperform
Merck price target raised to $82 from $70 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Merck to $82 and kept his Outperform rating, also raising his FY18 EPS view by 18c to $4.01 and FY19 view by 27c to $4.29. The analyst cites his increased confidence around the long-term growth potential of Keytruda and Gardasil and anticipates the company's revenue growing by mid-single digits until the loss of exclusivity for its Januvia program in 2022-23. Arfaei adds that his long-term forecasts are more bullish relative to the Street, with an added catalyst coming from Merck's potential diversification into Animal Health.
10/25/18
WELS
10/25/18
NO CHANGE
WELS
Wells Fargo says Trump speech today won't be end of drug pricing proposals
Wells Fargo analyst David Maris notes that Politico and other media outlets are reporting that President Donald Trump will propose several new initiatives to address high drug prices when he speaks later today at the U.S. Department of Health and Human Services. Maris thinks Trump's focus will be on how other countries are "freeloading" on U.S. innovation with lower negotiated pricing, stating that news reports make it appear that the administration is targeting the industry for action, rather than other countries to raise their spending. While Maris acknowledges the timing of the speech being near the mid-term elections, he believes these proposals are simply the follow-though of earlier promises. He also expects this is not the end of proposals to address the issue of U.S. drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/23/18
WOLF
10/23/18
INITIATION
Target $90
WOLF
Outperform
Merck reinitiated with an Outperform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated Merck with an Outperform and $66 price target.

TODAY'S FREE FLY STORIES

RIG

Transocean

$10.17

-0.36 (-3.42%)

12:40
11/12/18
11/12
12:40
11/12/18
12:40
Options
Transocean puts active as shares slip »

Transocean puts active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BX

Blackstone

$33.40

-0.59 (-1.74%)

12:35
11/12/18
11/12
12:35
11/12/18
12:35
Options
Blackstone put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATHN

Athenahealth

$132.00

11.63 (9.66%)

12:26
11/12/18
11/12
12:26
11/12/18
12:26
Downgrade
Athenahealth rating change  »

Athenahealth downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USO

United States Oil Fund

$12.90

0.205 (1.61%)

12:20
11/12/18
11/12
12:20
11/12/18
12:20
Options
Vote of confidence in US Oil Fund as shares tick higher »

Vote of confidence in US…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
11/12/18
11/12
12:17
11/12/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
11/12/18
11/12
12:16
11/12/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$9.80

-0.315 (-3.11%)

12:15
11/12/18
11/12
12:15
11/12/18
12:15
Options
Deutsche Bank put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$64.55

-1.18 (-1.80%)

12:13
11/12/18
11/12
12:13
11/12/18
12:13
Periodicals
Citi seeks bigger Paris office ahead of Brexit, FT reports »

Citigroup is eyeing a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 14

    Jan

  • 15

    Apr

  • 13

    Jul

CSLT

Castlight Health

$2.68

-0.01 (-0.37%)

12:11
11/12/18
11/12
12:11
11/12/18
12:11
Conference/Events
Castlight Health management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 27

    Nov

AAPL

Apple

$195.42

-8.89 (-4.35%)

, LITE

Lumentum

$38.36

-17.59 (-31.44%)

12:09
11/12/18
11/12
12:09
11/12/18
12:09
OnTheFly
Fly Intel: Wall Street's top stories at midday »

Stocks opened in negative…

AAPL

Apple

$195.42

-8.89 (-4.35%)

LITE

Lumentum

$38.36

-17.59 (-31.44%)

BABA

Alibaba

$142.11

-2.75 (-1.90%)

PCG

PG&E

$33.72

-6.17 (-15.47%)

EIX

Edison International

$55.03

-5.96 (-9.77%)

SAP

SAP

$101.49

-6.84 (-6.31%)

ATHN

Athenahealth

$132.04

11.67 (9.70%)

APTI

Apptio

$37.60

12.76 (51.37%)

OPK

Opko Health

$3.70

0.595 (19.16%)

BTI

British American Tobacco

$38.56

-3.18 (-7.62%)

GNC

GNC Holdings

$3.36

-0.87 (-20.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 26

    Nov

PHG

Philips

$37.67

-0.58 (-1.52%)

12:04
11/12/18
11/12
12:04
11/12/18
12:04
Hot Stocks
Philips announces first U.S. patient enrolled in ILLUMENATE BTK IDE study »

Royal Philips announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

MSI

Motorola Solutions

$127.46

-2.24 (-1.73%)

, MSFT

Microsoft

$106.99

-2.55 (-2.33%)

12:02
11/12/18
11/12
12:02
11/12/18
12:02
Hot Stocks
Motorola Solutions selects Microsoft Azure Government cloud for Command »

Motorola Solutions (MSI)…

MSI

Motorola Solutions

$127.46

-2.24 (-1.73%)

MSFT

Microsoft

$106.99

-2.55 (-2.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 26

    Nov

  • 28

    Nov

  • 03

    Mar

NAV

Navistar

$29.95

-0.34 (-1.12%)

, CMI

Cummins

$144.61

1.51 (1.06%)

12:01
11/12/18
11/12
12:01
11/12/18
12:01
Periodicals
EPA seeks to 'significantly' cut nitrogen oxide from heavy trucks, Reuters says »

The EPA on Monday intends…

NAV

Navistar

$29.95

-0.34 (-1.12%)

CMI

Cummins

$144.61

1.51 (1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 30

    Nov

EAF

GrafTech

$14.22

-1.86 (-11.57%)

12:00
11/12/18
11/12
12:00
11/12/18
12:00
Hot Stocks
GrafTech falls -11.6% »

GrafTech is down -11.6%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$33.59

-6.3 (-15.79%)

12:00
11/12/18
11/12
12:00
11/12/18
12:00
Hot Stocks
PG&E falls -15.8% »

PG&E is down -15.8%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 12

    Nov

GNC

GNC Holdings

$3.39

-0.845 (-19.98%)

12:00
11/12/18
11/12
12:00
11/12/18
12:00
Hot Stocks
GNC Holdings falls -19.8% »

GNC Holdings is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UVXY

ProShares Trust Ultra VIX Short Term Futures ETF

$54.60

4.55 (9.09%)

12:00
11/12/18
11/12
12:00
11/12/18
12:00
Hot Stocks
ProShares Trust Ultra VIX Short Term Futures ETF rises 9.2% »

ProShares Trust Ultra VIX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LABD

Daily S&P Biotech Bear 3x Shares

$39.51

4.09 (11.55%)

12:00
11/12/18
11/12
12:00
11/12/18
12:00
Hot Stocks
Daily S&P Biotech Bear 3x Shares rises 11.6% »

Daily S&P Biotech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCS

Barclays

$8.76

-0.39 (-4.26%)

12:00
11/12/18
11/12
12:00
11/12/18
12:00
Options
Put buyers in Barclays and implied volatility reaches 52-week highs »

Put buyers in Barclays…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSTI

Best Inc.

$6.10

0.92 (17.76%)

12:00
11/12/18
11/12
12:00
11/12/18
12:00
Hot Stocks
Best Inc. rises 17.0% »

Best Inc. is up 17.0%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 13

    Nov

JPM

JPMorgan

$109.16

-2.08 (-1.87%)

11:58
11/12/18
11/12
11:58
11/12/18
11:58
Periodicals
Bank of France works with JPMorgan to boost gold bullion services, Reuters says »

The Bank of France has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

11:55
11/12/18
11/12
11:55
11/12/18
11:55
Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call »

Alternative Energy…

11:53
11/12/18
11/12
11:53
11/12/18
11:53
Conference/Events
RBC Capital chemicals analyst to hold a group luncheon »

Chemicals Analyst…

11:51
11/12/18
11/12
11:51
11/12/18
11:51
Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call »

Alternative Energy…

11:50
11/12/18
11/12
11:50
11/12/18
11:50
Conference/Events
RBC Capital media analyst to hold a group luncheon »

Media Analyst Cahall…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.